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Role of Sodium-Glucose Cotransporter-2 Inhibitors in Readmissions for
Congestive Heart Failure
Abstract
Background
Background: Patients with type II diabetes are at major risk for cardiovascular disease. Sodium-glucose
cotransporter-2 inhibitors (SGLT-2 inhibitors) have demonstrated benefit for these patients. The purpose
of this study is to determine whether SGLT-2 inhibitors significantly reduce heart failure readmission rates
and improve outcomes in patients with congestive heart failure (CHF).
Methods
Methods: Patient data was pulled on CHF patients with an active prescription for an SGLT-2 inhibitor, and
it was analyzed using Fischer’s Exact tests and two-tailed t-tests. The primary outcome was a 6-month
hospital readmission rate due to CHF while taking SGLT-2 inhibitors. Secondary outcomes included
6-month all-cause hospital readmissions, renal function as measured by an estimated glomerular
filtration rate change between admissions, mortality rates, and ejection fraction.
Results
Results: Of the 138 patients that met inclusion criteria for the first admission, the 6-month all-cause
readmission rate for CHF patients still taking SGLT-2 inhibitors at readmission was 21 percent vs 16
percent (p=0.6) for the control group not taking SGLT-2 inhibitors. The 6-month CHF readmission rate in
patients taking SGLT-2 inhibitors was 7.2 percent, and a CHF specific readmission rate was not collected
for the control group. In patients with an eGFR less than 90, the average eGFR for the SGLT-2 group
declined slightly but was not significant between patients at first admission and those with readmission
(p=0.21).
Conclusion
Conclusion: The use of SGLT-2 inhibitors in patients with CHF did not change the overall hospital
readmission rate; however, larger randomized controlled trials are needed for further evaluation of the
potential benefit.
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ABSTRACT
Background: Patients with type II diabetes are at major risk
for cardiovascular disease. Sodium-glucose cotransporter-2
inhibitors (SGLT-2 inhibitors) have demonstrated benefit for
these patients. The purpose of this study is to determine
whether SGLT-2 inhibitors significantly reduce heart failure
readmission rates and improve outcomes in patients with
congestive heart failure (CHF). Methods: Patient data was
pulled on CHF patients with an active prescription for an
SGLT-2 inhibitor, and it was analyzed using Fischer’s Exact
tests and two-tailed t-tests. The primary outcome was a
6-month hospital readmission rate due to CHF while taking
SGLT-2 inhibitors. Secondary outcomes included 6-month
all-cause hospital readmissions, renal function as measured
by an estimated glomerular filtration rate change between
admissions, mortality rates, and ejection fraction. Results:
Of the 138 patients that met inclusion criteria for the first
admission, the 6-month all-cause readmission rate for CHF
patients still taking SGLT-2 inhibitors at readmission was
21 percent vs 16 percent (p=0.6) for the control group not

taking SGLT-2 inhibitors. The 6-month CHF readmission rate
in patients taking SGLT-2 inhibitors was 7.2 percent, and
a CHF specific readmission rate was not collected for the
control group. In patients with an eGFR less than 90, the
average eGFR for the SGLT-2 group declined slightly but was
not significant between patients at first admission and those
with readmission (p=0.21). Conclusion: The use of SGLT-2
inhibitors in patients with CHF did not change the overall
hospital readmission rate; however, larger randomized
controlled trials are needed for further evaluation of the
potential benefit.
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INTRODUCTION
Cardiovascular disease is the number one leading cause of death for
Americans.1 Congestive Heart Failure (CHF) is a prominent heart disease
marked by progressive structural changes in the heart, resulting in
inefficient filling and emptying of its chambers. An abnormality in
systolic function and/or diastolic function might be the cause of CHF.
Heart failure with reduced ejection fraction (HFrEF) results from a
reduced systolic function whereas heart failure with preserved ejection
fraction (HFpEF) is indicative of a preserved (normal) left ventricular
function.2 Many factors including age, gender, renal function, diabetes,
and medications can affect the prognosis of patients with CHF.3
Type II diabetes is a major contributing factor to the development of
heart disease as it is present as a comorbid condition in 25% to 40% of
patients with CHF.2,4 This noninsulin-dependent diabetes is caused by
β-cell dysfunction coupled with insulin resistance and defective insulin
secretion related to genetics and lifestyle factors.5 Commonly diagnosed
comorbid conditions for patients with type II diabetes are hypertension
and dyslipidemia. Therefore, diabetes does not only increase the risk of
CHF, but it also plays a significant role as predictor of morbidity and
mortality in patients with a previously established diagnosis of CHF.4,6
Data demonstrates that the link between diabetes and CHF may be more
pronounced than previously believed.7 The prevalence of heart failure
and type II diabetes is expected to continue rising in the United States

(US). Currently, 29 million adults in the US have type II diabetes and
6.5 million suffer from heart failure.8 The pathophysiology of diabetes
in HFpEF is demonstrated by an increased microvascular endothelial
inflammation accompanied with hyperinsulinemia resulting in cardiomyocyte stiffness and hypertrophy. Therefore, left ventricular diastolic
dysfunction worsens as a result of larger and stiffer cardiomyocytes. On
the other hand, cardiomyocyte death is more commonly seen in diabetic
patients with HFrEF.4 Since the pathophysiology of CHF and type II
diabetes seem to be strongly linked, drugs that improve diabetes may
also have efficacy for the treatment of CHF.
One option for treating type II diabetes is using a sodium-glucose
co-transporter-2 (SGLT-2) inhibitor, which treats this adult-onset diabetes
by inhibiting the reabsorption of glucose by the kidneys, thus preventing
high blood sugar levels. There is some evidence that these SGLT-2
medications may offer cardiovascular benefits. The 2021 American
Diabetes Association (ADA) guidelines state that SGLT-2 inhibitors
significantly reduce cardiovascular events, recommending their addition
in patients with type II diabetes and atherosclerotic cardiovascular
disease (ASCVD) with uncontrolled blood sugar while using metformin
or lifestyle modifications.9
SGLT-2 inhibitors are currently recognized by the ADA to reduce
cardiovascular events but are not included in heart failure guidelines as
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first-line agents. However, in the 2021 Update to the 2017 ACC Expert
Consensus Decision Pathway, SGLT-2 inhibitors are now recommended
as first-line therapy for all patients.10
At the time of this study, canagliflozin and empagliflozin were the only
SGLT-2 inhibitors United States Food and Drug Administration (FDA)
indicated for the prevention of cardiovascular outcomes in patients with
existing diabetes. Dapagliflozin has since been approved following the
DAPA-HF trial. These three SGLT-2 inhibitors have been shown to offer
improved outcomes in patients with HFrEF receiving guideline-directed
medical therapy.11,12
Empagliflozin was featured in EMPA-REG OUTCOME with a diverse
patient population, of whom 65% had a medical history of myocardial
infarction or stroke and all patients had greater than 12% risk for
cardiovascular events in 10 years. Patients on empagliflozin demonstrated
reductions in all-cause mortality, cardiovascular death, nonfatal infarcts,
and nonfatal strokes. The authors concluded that empagliflozin was able
to demonstrate consistent reduction in mortality and cardiovascular
events despite studying a patient population with a broad range of
cardiovascular histories and ASCVD risk.13
Among patients in the DAPA-HF trial with heart failure and a reduced
ejection fraction, the risk of worsening heart failure or death from
cardiovascular causes was lower among those who received dapagliflozin
than those who received placebo, regardless of the presence or absence
of diabetes. Dapagliflozin is the first SGLT-2 inhibitor to be approved for
patients independent of diabetes status.14
Like the authors of the DAPA-HF trial, we sought to gather data related to
the impact of SGLT-2 inhibitors. Our patient population had established
heart failure independent of diabetes status. Our study aimed to evaluate
the efficacy of SGLT-2 inhibitors in decreasing hospital admission rates
and improving the overall condition of heart failure. We also looked at
the usage of first-line CHF medications in our study to determine if
patients were on appropriate first-line therapy. For the established
treatment of CHF, first-line therapies include angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), beta-blockers, and diuretics as needed for fluid retention.14 The aim of the
present study is to investigate what benefit, if any, SGLT-2 inhibitors
provide to heart failure patients with or without diabetes for the possibility
of these medications becoming standard of care.

MATERIALS AND METHODS
The Institutional Review Board (IRB) of Sanford Health approved
our one-center retrospective cohort study on February 6th, 2020.
HIPAA authorization was waived for this approved IRB protocol #:
STUDY00001918, to evaluate the efficacy of SGLT-2 inhibitors in reducing
heart failure readmission rates. Patient data from 2013 to 2019 was
collected and analyzed for 6 months past the first admission. The sanford
Information Technology Department pulled patient information for
study inclusion criteria. Data collection took place at Sanford USD
Medical Center in Sioux Falls, South Dakota, from February to March
2020. Information was de-identified and analyzed from March to April
2020. Statistical analysis was done using Fischer exact tests and
two-tailed T-tests.
The primary outcome was 6-month hospital readmission rates due to
heart failure while taking SGLT-2 inhibitors. Secondary outcomes
included 6-month all-cause hospital readmissions, renal function as
measured by eGFR change between admissions, mortality rates, and
presence of HFrEF versus HFpEF while taking SGLT-2 inhibitors.
Inclusion Criteria
•
Patients 18 years or older with a diagnosis of CHF (as designated
by the International Classification of Diseases (ICD) 9/10 codes),
258

•
•

Patients require an active prescription for an SGLT-2 inhibitor,
Patients must have a creatinine clearance (CrCl) greater than
30 mL/min.

Exclusion Criteria
•
Patients with heart failure class IV, end-stage renal disease (ESRD),
and dialysis.
•
Patients who discontinued their SGLT-2 inhibitor before the second
admission.
At baseline, most patients were taking at least one first-line medication
for heart failure, suggesting proper management. For the first admission
for CHF, 138 patients met inclusion criteria. Of those, 72 patients were
taking either an ACE Inhibitor or an ARB, 88 were taking beta-blockers,
71 were taking diuretics, and 18 patients were not receiving any first-line
medication for CHF before hospitalization. Of those taking medications,
29 patients were taking one agent, 58 patients were taking two agents,
and 34 patients were taking more than two agents, as shown in Figure 1.
As a part of the inclusion criteria, all patients were taking an SGLT-2
inhibitor as shown in Figure 2. Most patients were taking canagliflozin
(51), while others were taking empagliflozin (40), dapagliflozin (21), or
a combination medication such as canagliflozin-metformin (7),
empagliflozin-linagliptin (6), or empagliflozin-metformin (2). Due to
the impact of the COVID-19 pandemic on data collection, no further
patient demographics were collected.
We were able to pull a matched cohort group to our data set so we could
compare readmission rates. A total of 78,000 patients with CHF from
2013 to 2019 who were not taking SGLT-2 inhibitors were included
in this data set. Due to time constraints of data collection and the
COVID-19 pandemic, we were unable to gather any additional information about this patient population other than readmission rates.

RESULTS
In patients taking SGLT-2 inhibitors, the 6-month all-cause readmission
rate was 21%, compared to a readmission rate of 16% in those patients
not taking SGLT-2 inhibitors.
Additionally, 10 of 138 patients (7.2%) taking a SGLT-2 inhibitor were
readmitted for a specific diagnosis of CHF as depicted in Figure 3.
A readmission rate for a specific diagnosis of CHF was not collected
for the control group not taking SGLT-2 inhibitors. A Fisher Exact test
comparing all-cause readmission rate of those taking SGLT-2 inhibitors
to the control group produced a P-value of 0.6, which was not significantly different.

Figure 1: Baseline heart failure medication use.
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Figure 2: SGLT-2 inhibitor breakdown.

Figure 5: Prevalence of HFrEF vs. HFpEF first admission.

Figure 3: Readmission rates on SGLT-2 inhibitors.

Figure 6: Prevalence of HFrEF vs. HFpEF at readmission.

(62%) as shown in Figures 5 and 6. These changes were not significant
(p=0.81). Patients who did not have a recent echocardiogram within one
month of admission were excluded.
During the first admission, 1 out of 131 patients did not have a diagnosis
of type II diabetes. During the second admission, all 29 patients had a
diagnosis of type II diabetes.
The study also evaluated mortality rate of those taking SGLT-2 inhibitors
and who also were diagnosed with CHF. Patients who died after 6 months
of their first admission were included in this mortality rate. At data
collection, 20.3% of patients with a first admission had died. Unfortunately, similar to other endpoints, mortality rate could not be compared
to a control group due to COVID restrictions.

DISCUSSION
Figure 4: eGFR change between admissions. (p=0.21).

In patients with an eGFR less than 90, the average eGFR for the SGLT-2
group declined slightly but non-significantly from 57.9 mL/min/1.73m2
to 52.8 mL/min/1.73m2 between patients at first admission and those
with readmission (p=0.21) as shown in Figure 4.
The prevalence of HFpEF and HFrEF was comparable between first
admission and those with readmission, with 35 of 105 first time admits
(33%) and 8 of 21 second time admits (38%) reporting HFrEF with an
ejection fraction <40%. The rest of the patients with data were HFpEF,
with 70 of 105 first time admits (67%) and 13 of 21 second time admits
Journal of Young Pharmacists, Vol 13 Issue 3, Jul-Sep, 2021

The 6-month all-cause readmission rate for patients taking SGLT2inhibitors was not significantly different than the readmission rate for
those not taking SGLT-2 inhibitors (21% vs 16%). These 6-month
readmission rates were lower than the reported statistic from the 2013
American College of Cardiology (ACC)/American Heart Association
(AHA) Heart Failure Guidelines, where patients hospitalized for CHF
had a 1-month readmission rate of 25% for all-cause rehospitalization.15,16
The mortality rate of 20.3% in this study was similar to that reported
in the 2013 American College of Cardiology Foundation (ACCF)/AHA
Heart Failure Guidelines. According to the 2013 ACCF/AHA Heart
Failure Guidelines, the absolute mortality rates for CHF remain
approximately 50% within 5 years of diagnosis. In the ARIC study, the
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30-day, 1-year, and 5-year case fatality rates after hospitalization for CHF
were 10.4%, 22%, and 42.3%, respectively.17
We found no significant differences with HFrEF or eGFR, so our data
cannot be used to support efficacy for renal or heart failure outcomes.
This study has some limitations. Since our data was collected using
diagnostic codes, a patient might have been coded for CHF even if it was
not the main cause of the admission. Therefore, to find the CHF specific
readmission, we did a manual chart review to find where CHF was listed
as a cause of the admission according to provider documentation, which
may be subject to error.
Another major limitation of this study was small sample size. The
primary outcome statistical result could be due to a type II error where
we failed to find a difference although one may have existed if we had a
larger sample size. Due to the small number of patients in the readmission
group, we were unable to perform some of the exploratory analyses
that we planned. We did not perform subgroup analysis by individual
SGLT-2 inhibitor, or look at a subset analysis of patients without diabetes
that were taking a SGLT-2 inhibitor.
This study also had several strengths. A strength of this study is that
most patients received appropriate first-line therapy for CHF (120 of 138
patients), so we can be sure that patients were receiving some treatment
for CHF. However, the effect of the other therapies for CHF on these
results was not studied. Another strength was that patients were well
distributed between SGLT-2 inhibitors, so we were able to look at the
class benefit of SGLT-2 inhibitors.
It was also positive that there was not a significant decrease in average
eGFR between readmissions. This could be interpreted as SGLT-2
inhibitors preventing a decline in renal function and a topic for future
clinical research. It should be noted that those patients with eGFR
>90 mL/min/1.73m2 (normal renal function) were not included in the
statistical analysis to prevent skewing the data. Other strengths of this
study include a large health system to pull data, a matched cohort control
group to compare readmission rates, and limited exclusion criteria.
For future direction, it would also have been beneficial to extend data
collection for readmissions longer than 6 months to increase sample size.
Finally, it is important to note that CHF is most often accompanied with
a multitude of other disorders and comorbidities that can affect patients’
treatment approach, morbidity, and mortality differently.

CONCLUSION
The use of SGLT-2 inhibitors in patients with CHF did not significantly
change the overall hospital readmission rate; however, this study reports
better readmission values than those reported in the literature. Larger
randomized controlled trials are needed for further evidence of this
indication. More data could help incorporate SGLT-2 inhibitors into
standard care for heart failure. Now that dapagliflozin is approved as an
adjunct heart failure agent, we hope that this study aids clinicians in the
use of SGLT-2 inhibitors. Safety and cost are variables that would need
to be addressed. Head-to-head trials of SGLT-2 inhibitors would help
prescribers choose the best agent.
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